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Here, we isolated, expanded and functionally characterized regulatory T cells (Tregs)
from patients with end stage kidney and liver disease, waiting for  kidney/liver
transplantation (KT/LT), with the aim to establish a suitable method to obtain large
numbers of immunomodulatory cells for adoptive immunotherapy post-transplantation.
METHODS:
We first established a preclinical protocol for expansion/isolation of Tregs from
peripheral blood of LT/KT patients. We then scaled up and optimized such protocol
according to Good Manufacturing Practice (GMP) to obtain high numbers of purified
Tregs which were phenotypically and functionally characterized in vitro and in vivo in a
xenogeneic acute graft-versus-host disease (aGVHD) mouse model. Specifically,
immunodepressed mice [NOD-SCID-gamma KO mice] received human effector T cells
with or without GMP-produced Tregs to prevent the onset of xenogeneic GVHD.
RESULTS:
Our small scale Treg isolation/expansion protocol generated functional Tregs.
Interestingly, cryopreservation/thawing did not impair phenotype/function and DNA
methylation pattern of FOXP3 gene of the expanded Tregs. Fully functional Tregs were
also isolated/expanded from  KT and  LT patients according to GMP. In the mouse
model, GMP Tregs from  LT or  KT patient proved to be safe and show a trend toward
reduced lethality of acute GVHD.
CONCLUSIONS:
These data demonstrate that expanded/thawed GMP-Tregs from patients with end-
stage organ disease are fully functional in vitro. Moreover, their infusion is safe and
results in a trend toward reduced lethality of acute GVHD in vivo, further supporting
Tregs-based adoptive immunotherapy in solid organ transplantation.
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Order of Authors Secondary Information:
Response to Reviewers: Reviewer reports:
Reviewer #1: The manuscript submitted by Ulbar et al. describes phenotyping and
functional analysis of CD4+ Treg of patients with end-stage liver and kidney disease.
There is particular emphasis on the use of GMP-compliant Treg manipulation
protocols, implying that the same cells may be used for human therapy. This makes
perfect sense as the working hypothesis is that adoptive transfer of such autologous
Treg may be used as prophylaxis/therapy to preclude liver/kidney rejection upon solid
organ transplantation. The authors demonstrate that their Treg display a stable
phenotype, expand and exert Treg-mediated suppression of T cell responses both in
vitro and in vivo. The latter is tested in a xenogeneic model of aGvHD.
This is a well-written, well-presented manuscript that raises an interesting question.
The authors use adequate, seemingly GMP compliant sorting and expansion
methodology, acceptable Treg staining panels, in vitro assays, and a state-of-the-art
humanized mouse model of aGvHD to test Treg activity in vivo; PBMC-NSG mice have
been used by multiple authors to assess Treg function indeed.
Major criticisms:
1) The key question is whether these cells could be used to prevent kidney/liver
rejection upon solid organ transplantation. This reviewer believes that the paper does
not provide any clear evidence to support this notion, which diminishes enthusiasm. In
order to address this issue, it must be somehow demonstrated that these Treg are fully
functional in the kidneys/liver in vivo. At a bare minimum, the authors need to assess
Treg-mediated suppression of liver damage in their mice, by histology. NSG mice
develop liver aGvHD upon transplantation PMID: 19659776 and this could be used as
a surrogate marker to assess Treg-mediated suppression of T-cell mediated "rejection"
of the liver. Certainly, a more adequate approach would be to use double-humanized
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NSG mice (FRGN) having an MHC mismatched human liver (donor# 1) and human
hematopoietic system (donor #2), as described here: PMID: 25310256. The best
approach would be testing the same question on NSG mice receiving an actual liver
graft from an independent, MHC mismatched human donor.
WE AGREE WITH THE REFEREE THAT DOUBLE-HUMANIZED NSG MICE WOULD
BE THE BEST  MODEL TO EVALUATE THE EFFECTS OF TREG INFUSIONS.
HOWEVER,  IT IS IMPORTANT  TO POINT OUT THAT IN OUR PAPER WE AIMED
TO TEST WHETHER TREGS FROM  LT OR KT PATIENTS WERE CAPABLE OF
PREVENTING/HALTING GVHD AS A PROOF OF THEIR FUNCTIONAL ACTIVITY.
FOR THIS PURPOSE, WE FUNCTIONALLY CHARACTERIZED  THE
EXPANDED/THAWED TREGS FROM LT AND KT PATIENTS BOTH IN VITRO AND
IN VIVO (BY USING A XGVHD MOUSE MODEL).  WE ALSO AGREE THAT IT
WOULD BE INTERESTING TO ANALYZE WHETHER TREGS FROM LT OR KT MAY
PREVENT A GVHD IN THE LIVER. IN OUR MOUSE MODEL, AGVHD WAS VERY
AGGRESSIVE AND WEIGHT LOSS WAS A VERY EARLY SIGN OF DISEASE AND
RAPIDLY ASSOCIATED WITH DEATH.  CONSEQUENTLY, SINCE MOST MICE
DIED OVERNIGHT, WE WERE UNABLE TO COLLECT EITHER THE LIVER OR
OTHER ORGANS. WE BELIEVE, HOWEVER, THAT OUR DATA, BOTH IN VITRO
AND IN VIVO,  STRONGLY SUGGEST THAT THE EXPANDED/THAWED TREGS
FROM LT AND KT PATIENTS ARE FULLY FUNCTIONAL.
2) It is not clear to me whether the authors expand t/nTreg or p/iTreg cells or a mixture
of them, which are quite different in many aspects. Among others, in terms of
phenotypic stability, which is a key question here. If the authors were to use circulating
Treg from healthy donors, we could call them bona fide tTreg. But as they use
diseased patients, Treg origin and status remains an open question, even after
methylation assays. I guess the majority of the cells is tTreg, but pTreg contamination
may affect the results. E.g. it might explain the limited suppressive capacity observed.
Markers of these subsets are a matter of ongoing debate, but the authors may
consider using Helios, NRP-1 or other markers of these subsets to provide the reader
with some information in this regard.
AS UNDERLINED BY THE REFEREE, FRESHLY ISOLATED CELLS FROM THE
DISEASED PATIENTS MAY INCLUDE EITHER T/NTREG OR P/ITREG. HOWEVER,
IN THIS PAPER WE AIMED TO CHARACTERIZE NOT THE FRESHLY ISOLATED
CELLS BUT THE 21 DAYS EXPANDED TREGS WHICH ARE THE CANDIDATE
CELLS TO BE INFUSED. INDEED,  EXPANDED  TREGS FROM DISEASED
PATIENTS HAVE BEEN DEMONSTRATED TO BE PHENOTIPICALLY STABLE  AND
FUNCTIONALLY ACTIVE.
Minor criticisms:
3) In different EU member countries, GMP compliance is tested by various bodies and
organizations. A statement regarding the name of the authority that validated GMP
compliance in this study would be required.
THE GMP MANUFACTURING WAS PERFORMED IN THE CELL FACTORY OF
FONDAZIONE IRCCS CA’ GRANDA OSPEDALE MAGGIORE POLICLINICO IN
MILAN, CERTIFIED IN COMPLIANCE WITH THE EUROPEAN GMP REGULATIONS
BY THE ITALIAN DRUG AGENCY FROM 2007 (LAST AUTHORIZATION NUMBER
Am-51/2018)
4) Please state which Foxp3 region has been studied in methylation assays. Is this
CNS2?
AUTHORS CONFIRM THAT CNS2 REGION OF FOXP3 HAS BEEN ANALYZED IN
METHYLATION ASSAY.  METHODS SECTION HAS BEEN MODIFIED
ACCORDINGLY.
5) Page 9 Line 26: I believe that characterizing "CD8-CD25- T cells" as "Teff" is rather
problematic. Just state "CD8-CD25- T cells".
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AS SUGGESTED, WE MODIFIED THE TEXT ACCORDINGLY
6) Page 7 line 36: Please specify the exact Miltenyi beads used and MACS sorting
platform used
THE REQUESTED INFORMATIONS HAS BEEN ADDED IN THE MATERIAL AND
METHODS SECTION
7) Some minor typos:
Page 11 Line 56 intraperitoneally transfer
Page 12 Line 24 CD4 is listed twice in the panel. Is it CD127?
Page 18 Line 15 Tregs numbers
Page 18 Line 30 conflict findings
AS SUGGESTED, WE MODIFIED  THE TEXT ACCORDINGLY
Taken together, I believe that the manuscript has merit but it has some shortcomings
that need to be addressed before publication.
Reviewer #2: Minor points
Are you sure the first and last author equally contributed? It is not rather the first and
second? (check the symbols)
FIRST (UF) AND SECOND AUTHOR (MT) CONTRIBUTED EQUALLY AND ARE
IDENTIFIED WITH°
LAST (LRM) AND CO-LAST (CL) AUTHOR CONTRIBUTED EQUALLY AND ARE
IDENTIFIED WITH §
Please clarify the negative fraction used as effector T cells. Is the fraction CD8-? In that
case the GVHD model relies only on CD4 T effector cells? If so, discuss the difference
in the GVHD mouse models between regular CD8 T effector and CD4 T effectors in
terms of GVHD severity and T reg GVHD rescue capacity.
PBMCS HAVE BEEN PREVIOUSLY  USED AS EFFECTOR CELLS IN A
XENOGENEIC MODEL OF GVHD AND TREGS HAVE BEEN SHOWN TO REDUCE
GVHD LETHALITY IN IMMUNODEFICIENT MICE (HIPPEN  KL ET AL. SCI TRANSL
MED 2011;3(83):83ra41; HANNON M ET AL. TRANSFUSION 2014;54:353; DEL
PAPA B ET AL. BIOL BLOOD MARROW TRANSPLANT 2017;23:1847). DUE TO THE
FACT THAT MOST STUDIES USED PBMC AS EFFECTOR CELLS IS VERY
DIFFICULT TO COMPARE CD4- VS CD8-BASED GVHD.
HOWEVER, IT HAS BEEN PREVIOUSLY SHOWN THAT TREGS SUPPRESS CD4 T
CELL ACTIVATION AND PROLIFERATION BY CONTACT-DEPENDENT AND
CONTACT-INDEPENDENT MECHANISMS (SCHMIDT A ET AL. 2012;3:51).
ADDITIONALLY, TREGS CAN ALSO INFLUENCE PROLIFERATION, ACTIVATION
AND APOPTOSIS OF CD8+ T CELLS  (NIKOLOVA M ET AL. BLOOD (2009)
113:4556–65;  BOETTLER T ET AL. J VIROL. (2005) 79:7860–7). BASED ON AN IN
VITRO HUMAN SKIN EXPLANT GVHD MODEL, WANG X ET AL
(TRANSPLANTATION. 2009;88:188-97) DEMONSTRATED THAT DONOR-DERIVED
TREGS EFFECTIVELY SUPPRESS CD8_ T-CELL-MEDIATED GVH TISSUE
DAMAGE BUT ARE CRITICALLY REQUIRED DURING PRIMING OF EFFECTOR T
CELLS. SIMILARLY, IN THIS STUDY WE DEMONSTRATED THAT CD4 ENRICHED
CELLS ARE CAPABLE TO INDUCE AN ACUTE GVHD IN NSG MICE AND THAT
EARLY INFUSION OF TREGS FROM LT OR KT  PATIENTS HAS THE POTENTIAL
TO AMELIORATE THE GVHD LETHALITY.
Escalated the protocol  please change: scaled-up the protocol
TEXT MODIFIED ACCORDINGLY
Background, page 6 line 3: proved instead of proven
TEXT MODIFIED ACCORDINGLY
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Methods, page 6, line 25, please harmonize the exclusion criteria with the data of
patient Table I where you included LT patients with HCV/HBV liver cirrhosis. At least
specify in the criteria that you allowed viral mediated organ failure, while you had a
cutoff on the viremia? Also, please for clarity fill the table with Y N or NA or ND (not
done) or Not Available Data instead of "/".
I did not found the table legend.
TABLE I SHOWS CLINICAL DATA OF ALL PATIENTS STUDIED FOR IN VITRO AND
GMP IN VIVO EXPERIMENTS.  PATIENTS OF THE IN VITRO EXPERIMENTS
INCLUDED ALSO VIRUS-RELATED END STAGE ORGAN FAILURE. CONVERSELY,
THE CRITERIA OF ENROLMENT IN THE PROTOCOL OF GMP TREG
ISOLATION/EXPANSION AND IN VIVO INJECTION  EXCLUDED PATIENTS WITH
VIRUS-RELATED END STAGE ORGAN FAILURE. THIS SPECIFICATION HAS NOW
BEEN ADDED IN THE TEXT.
Page 9, line 10: if bisulphite conversion reaction runs to completion  run
TEXT MODIFIED ACCORDINGLY
Results, page 14 line 39: "From the functional point of view" … please improve the
English form
TEXT MODIFIED ACCORDINGLY
Discussion page 18, line 40 : Tregs from LT or KT patients proven  proved
TEXT MODIFIED ACCORDINGLY
Discussion page 18, line 48: We also found that in vivo GMP Tregs from LT patients
were more effective than KT counterparts in halting GVHD  due to the number of
samples: 1 and 1 for each group, this is comparison is not possible.
WE AGREE WITH THE REFEREE AND WE  DELETED THE TEXT ACCORDINGLY
Reviewer #3: The manuscript by Ulbar et al is well-written and addresses the use of
expanded Tregs for solid organ transplants and GVHD. However, the impact of Treg
infusion for preventing GvHD is quite labile in the manuscript.
I kindly ask the authors to comment and/or clarify the following points:
-There are several publications on Tregs as safe and effective treatment of GVHD and
Type 1 diabetes (refences 12-17 in the manuscript), while few results have been
published on clinical trials testing the efficacy of Tregs in solid organ transplantation.
What is the novelty brought by the present manuscript on this regard? The same
authors state: "Our data are consistent with previous models of xenogenic GVHD and
Treg infusion."
AS UNDERLINED BY THE REFEREE, FEW RESULTS HAVE BEEN PUBLISHED ON
CLINICAL TRIALS TESTING THE EFFICACY OF TREGS IN SOLID ORGAN
TRANSPLANTATION. OUR DATA FURTHER SUPPORT THE USE OF GMP
EXPANDED/THAWED T-REGS FOR  ADOPTIVE IMMUNOTHERAPY IN SOLID
ORGAN TRANSPLANTATION. IN ADDITION, FOR THE FIRST TIME BOTH KT AND
LT TREGS WERE EXPANDED AND FUNCTIONALLY ANALYZED WITH THE SAME
ISOLATION/EXPANSION PROTOCOL.
-The authors state that "In the mouse model, GMP Tregs from LT and KT patient
proven to be safe and may improve acute GVHD", or "with the potential of alleviating
GVHD". However, this has not been demonstrated in the presented set of experiments
(no statistical significance between Teff vs Teff-T reg infusions in the mouse model).
FOLLOWING REFEREE’S COMMENT, WE MODIFIED THE TEXT (DISCUSSION
SECTION) POINTING OUT THAT IN VIVO INFUSION OF TREGS FROM DISEASED
PATIENTS INDUCED ONLY A TREND TOWARD A REDUCTION OF GVHD
LETHALITY.
-HBV/HCV are listed as exclusion criteria, however 8 patients with HCV/HBV cirrhosis
are reported in table 1.
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TABLE I SHOWS CLINICAL DATA OF ALL PATIENTS STUDIED. SPECIFICALLY, IN
VITRO ASSAYS HAVE BEEN PERFORMED WITH CELLS DERIVED FROM
PATIENTS WITH OR WITHOUT VIRUS-RELATED END STAGE ORGAN FAILURE.
CONVERSELY,  IN VIVO EXPERIMENTS  HAVE BEEN PERFORMED ONLY WITH
CELLS FROM PATIENTS WITHOUT VIRUS-RELATED END STAGE ORGAN
FAILURE . THE TEXT (MATERIAL AND METHODS SECTION) HAS BEEN
MODIFIED ACCORDINGLY.
-It is stated that the purity at isolation after Miltenyi negative selection and enrichment
is more than 90%. However, later on in the manuscript it is reported that "the median
Treg purity was 72% (range 50-84) and 55% (range 40-70) in LT and KT patients…".
We acknowledge that the purity significantly improves after in vitro expansion.
THESE FINDINGS ARE DUE TO THE FACT THAT AFTER ISOLATION, THE PURITY
OF CD4+CD25+ T CELLS WAS ALWAYS >90%. THE CD4+CD25+CD127-FOXP3 +
T CELLS WERE AS DESCRIBED.
-Teff cells as well as negative fraction are always referred as CD8-CD25- T cells
creating confusion along all the paper.
THE NEGATIVE FRACTION CD8-CD25- T CELLS WAS USED TO TEST THE IN
VITRO SUPPRESSIVE ACTIVITY OF THE FRESHLY ISOLATED/EXPANDED
TREGS AND IN THE IN VIVO ACUTE GVHD MODEL. THE TEXT WAS MODIFIED
ACCORDINGLY
-How polyclonality of Tregs was assessed?
WE DID NOT ASSESS THE POLYCLONALITY OF THE EXPANDED TREGS.
INDEED, IT HAS BEEN PREVIOUSLY DEMONSTRATED THAT THE STIMULATION
WITH CD3/CD28 BEADS ALLOWS THE EXPANSION OF ONLY POLYCLONAL
TREGS (SAFINIA N ET AL. ONCOTARGET 2016; DEL PAPA ET AL BIOL BLOOD
MARROW TRANSPLANT 2017). THUS,  WE ASSUMED THAT EXPANDED TREGS
WERE POLYCLONAL. HOWEVER, TO AVOID CONFUSING WORDS ,
POLYCLONAL HAS NOW BEEN DELETED FROM THE TEXT.
- The very low immunosuppressive activity of Tregs freshly isolated is quite impressive.
The authors claim that this could be attributable to the low purity after isolation.
WE AGREE WITH THE REFEREE. OUR RESULTS ARE IN CONTRAST WITH
PREVIOUS FINDINGS (DEL PAPA B ET AL, 2017; SAFINIA N ET AL . 2018)
SHOWING THAT THE SUPPRESSIVE ACTIVITY OF FRESHLY ISOLATED CD8-
CD19-CD25+ CELLS (DEL PAPA B ET AL. 2017) OR CD8-CD25+ CELLS (SAFINIA N
ET AL. 2018) FROM HEALTHY INDIVIDUALS IS AROUND  60-80%  AT 1:1
TREG/TCONS RATIO.  WE BELIEVE THAT THE POOR  RESULTS OF IN VITRO
IMMUNOSUPPRESSIVE ACTIVITY OF FRESHLY ISOLATED TREGS WERE
MAINLY DUE  TO THE MAXIMUM WORKING RATIO OF 1:2 TREG/CD8-CD25- T
CELLS.  IN ADDITION, THE PURITY OF OUR FRESHLY ISOLATED CELLS
(CD4+CD25+CD127-FOXP3+) FROM HEALTHY DONORS WAS AROUND 65%. OF
NOTE, AFTER 21 DAYS OF EXPANSION, THE PURITY  INCREASED
SIGNIFICANTLY.
-Some references are reported in red.
WE MODIFIED THE REFERENCE SECTION
********
Manuscript Classifications: 30.010: Adoptive immune therapy
Additional Information:
Question Response
<b>Is this study a clinical No;
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trial?</b><hr><i>A clinical trial is defined
by the Word Health Organisation as ‘any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes’.</i>
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Abstract     
 
BACKGROUND: 
Here, we isolated, expanded and functionally characterized regulatory T cells (Tregs) from 
patients with end stage kidney and liver disease, waiting for  kidney/liver transplantation (KT/LT), 
with the aim to establish a suitable method to obtain large numbers of immunomodulatory cells for 
adoptive immunotherapy post-transplantation. 
METHODS: 
We first established a preclinical protocol for expansion/isolation of Tregs from peripheral 
blood of LT/KT patients. We then scaled up and optimized such protocol according to Good 
Manufacturing Practice (GMP) to obtain high numbers of purified Tregs which were phenotypically 
and functionally characterized in vitro and in vivo in a xenogeneic acute graft-versus-host disease 
(aGVHD) mouse model. Specifically, immunodepressed mice [NOD-SCID-gamma KO mice] 
received human effector T cells with or without GMP-produced Tregs to prevent the onset of 
xenogeneic GVHD. 
RESULTS: 
Our small scale Treg isolation/expansion protocol generated functional Tregs. Interestingly, 
cryopreservation/thawing did not impair phenotype/function and DNA methylation pattern of 
FOXP3 gene of the expanded Tregs. Fully functional Tregs were also isolated/expanded from  KT 
and  LT patients according to GMP. In the mouse model, GMP Tregs from  LT or  KT patient 
proved to be safe and show a trend toward reduced lethality of acute GVHD.  
CONCLUSIONS: 
These data demonstrate that expanded/thawed GMP-Tregs from patients with end-stage 
organ disease are fully functional in vitro. Moreover, their infusion is safe and results in a trend 
toward reduced lethality of acute GVHD in vivo, further supporting Tregs-based adoptive 












































































































































Regulatory T cells (Tregs) 
Kidney transplantation (KT)  
Liver transplantation (LT) 
Good Manufacturing Practice (GMP) 
Acute graft-versus-host disease (aGVHD) 
Graft-versus-host disease (GVHD) 
Immunosuppressive (IS) 
Peripheral blood (PB) 
White blood cell (WBC) 
Ethylenediaminetetraacetic acid (EDTA) 
Peripheral blood mononuclear cells (PBMC) 
Treg-specific demethylation region (TSDR) 
Carboxyfluorescein succinimidyl ester (CFSE) 
Roswell Park Memorial Institute (RPMI) 
Fetal Bovine Serum (FBS) 
Acid citrate dextrose (ACD) 
Dimethyl sulfoxide (DMSO) 
Human serum albumin (HSA) 






































































Organ transplantation is the only curative treatment for patients affected by end-stage liver 
or kidney disease. Although immunosuppressive (IS) drugs have reduced the incidence of acute 
rejection and transplantation-associated mortality, their administration is associated with major side 
effects, such as opportunistic infections, damage of transplanted organs and secondary cancer [1,2]. 
Therefore, new strategies to improve long-term graft survival while reducing/eliminating IS therapy 
and, ideally, inducing immunological tolerance are needed.      
Cellular therapy can improve the outcome of solid organ transplantation through anti-
inflammatory effects and the induction of immune tolerance. T cell-mediated immunomodulation is 
one of the main mechanisms to maintain operational tolerance (withdrawal of immunosuppressive 
drugs while maintaining normal graft function and histology) in vivo. It is now accepted that 
regulatory T cells (Tregs), a subpopulation of T helper lymphocytes, are responsible for this 
immunomodulatory activity, as a result of their suppressive effects directly on effector T cells and 
on antigen presenting cells [3,4]. Circulating Tregs constitutively express CD25 and FoxP3 and 
represent 5–10% of all peripheral CD4+ T cells [5,6]. Tregs, which are fundamental for the 
maintenance of immune homeostasis, demonstrated a key role for transplantation tolerance in 
animal models by impairing the function of CD8+ T cells [7-10]. In humans, cell therapy with 
human Tregs for the induction of transplantation tolerance represents a promising strategy [10,11]. 
Indeed, clinical trials using this approach have already demonstrated that expanded polyclonal and 
antigen-specific Tregs are safe and effective in the treatment of GVHD and Type 1 diabetes [12-
17]. Conversely, very few results have been published on clinical trials testing the efficacy of Tregs 
in solid organ transplantation [18,19]. Moreover, isolated/ex vivo expanded Tregs have been only 
tested in animal models [20-22].  
Here, we first established a preclinical protocol for expansion/isolation of Tregs from 
patients with end-stage liver or kidney disease being in the waiting list for liver/kidney 



































































Manufacturing Practice (GMP) to obtain high numbers of purified Tregs which were tested in vitro 
and in a xenogeneic acute graft-versus-host disease (GVHD) mouse model. 
 
Materials and Methods 
 
Patients 
Peripheral blood (20-60 mL) was obtained from 14 LT and 9 KT patients. Patients characteristics 
are outlined in Table I.  Patient selection for GMP Tregs isolation/expansion was based on the 
following inclusion criteria: 1) Age ≥ 18 years; 2) Diagnosis of end-stage kidney disease in waiting 
list for living donor kidney transplantation or diagnosis of end-stage liver disease in waiting list for 
liver transplantation. Exclusion criteria included: 1) HIV, HBV, HCV positivity; 2) syphilis 
antibody positivity; 3) combined transplant; 4) concurrent uncontrolled infection. Patient selection 
for in vitro experiments were as above described except virus positivity. Peripheral blood (20-60 
mL) and buffy-coat (30 mL) were also obtained from age and sex matched healthy controls. Human 
studies were conducted in accordance with the Declaration of Helsinki and approved by the local 
ethical Committee (232/2015/O/Tess by Investigation Drug Service, Azienda Ospedaliero-
Universitaria di Bologna). Informed consent was obtained from all the subject prior to enrollment 
into the study.  
 
 
Circulating Treg enumeration  
Enumeration by flow cytometry of circulating Treg (CD4+CD25+CD127-FoxP3+) was carried out 
in the peripheral blood (PB) of selected KT and LT patients (n=7 and n=10, respectively) and of 



































































Table I. Surface marker staining was performed for 15 min at room temperature.  For intracellular 
staining, anti-human FoxP3 (PCH101) Staining Set PE Kit was used (eBiosciences), according to 
the manufacturer’s instructions. Isotype control rat IgG2 PE was used as a control. Briefly, cells 
were stained for surface markers CD4, CD25 and CD127, washed once in PBS and then 
fixed/permeabilized. After washing, cells were incubated with anti-human FoxP3 antibody for 30 
minutes at 4 ºC in the dark. A lysis buffer (Becton Dickinson) was used in order to lysate red blood 
cells. The phenotype of Tregs was analyzed by flow cytometry FACSCantoII (Beckton Dickinson). 
Data were analyzed using the FACSDiva software (Becton Dickinson). The percentage of positive 
cells was calculated by subtracting the value of the appropriate isotype controls. The absolute 
number of positive cells per µL was calculated as follows: percentage of positive cells × white 
blood cell count (WBC)/ 100.  
 
 
Tregs isolation and expansion 
EDTA-anticoagulated peripheral blood (60 ml) was collected from 4 LT patients, 2 KT patients and 
buffy-coat (30 ml) from 5 controls. Peripheral blood mononuclear cells (PBMC) were then isolated 
by Ficoll-Hystopaque density gradient centrifugation.  
Isolation: freshly isolated CD8-CD25+T cells were purified from PBMC by negative selection of 
CD8+T cells followed by positive selection of CD25+T cells using specific Miltenyi-Biotec Beads 
(CD8 microbeads human and CD25 microbeads II human) with  MidiMACS separator and a purity 
(CD4+CD25+) of  >90% .  
Expansion: freshly isolated cells were plated at 1×106/ml cells and activated with anti-CD3/CD28 
coated beads (Invitrogen, Paisley, UK; Miltenyi Biotech) at a 4:1 bead:cell ratio at day 0 and then 
1:1 bead:cell ratio weekly. Cells were expanded in culture media (TECSMacs GMP medium, 
Miltenyi Biotech) 5% human AB plasma containing rapamycin (100 nM) (Rapamune®, Wyeth, 
USA) for 21 days at 37°C and 5% CO2. IL-2 (1000 IU/ml, Proleukin



































































day 4 post-activation and replenished every 2 days. Cells were restimulated with beads every 7 
days. After 21 days of culture, beads were magnetically removed and the cells washed in 
TECSMacs GMP medium. After washings, fresh beads, rapamycin and IL-2 were added. Expanded 
cells were used for further analysis at each time of re-stimulation up until day 21 of expansion.  
 
 
Phenotypic characterization  
Phenotypic characterization were performed on day 0,7,14,21 of cultures for ex vivo expansion  and 
after cryopreservation/thawing by flow cytometry as above described.  Surface marker staining was 
performed in order to asses the content of Tregs and contaminant cells (monocytes (CD14+), B 
(CD19+) and T cells (CD8+), NK cells (CD56+), Th17 cells (CD196+CD161+)) present at each 
time point of culture (Supplementary Table I) . 
 
 
FOXP3 promoter demethylation analysis 
The highly conserved Treg-specific demethylation region (TSDR) within the human FOXP3 gene is 
demethylated exclusively on Tregs and not in any other blood-cell types. Specific DNA methylation 
of the Treg FOXP3 is referred to intron 1, as previously identified [23]. DNA methylation of 
FOXP3 gene  (CNS2 region) of expanded cells (day +21), either freshly isolated or after 
cryopreservation/thawing, was evaluated for a total of 6 subjects (3 patients: 1 KT and 2 LT 
patients; and 3 controls). Genomic DNA was extracted from purified Tregs using the AllPrep 
DNA/RNA Mini Kit (QIAGEN, Hilden, Germany). 500ng of DNA was bisulphite-converted using 
the EZ DNA Methylation Kit (Zymo Research Corporation, Orange, CA) according to 
manufacturer’s instructions, except for the thermal conditions of the conversion (21 cycles of 55°C 
for 15 min and 95°C for 30s). Bisulphite-treated DNA was eluted in 100ul of water. DNA 



































































was performed by EpiTYPER assay (Sequenom, San Diego, CA), a quantitative method based on 
mass spectrometry  that allows to evaluate methylation level at single CpG sites/groups of adjacent 
CpG sites (CpG units). Ten ng of bisulphite-treated DNA were PCR-amplified and processed 
following manufacture’s instructions. The bisulphite specific primers were: FOXP3 forward, 
AGGAAGAGAGATTTGTTTGGGGGTAGAGGATTTA; FOXP3 reverse, 
CAGTAATACGACTCACTATAGGGAGAAGGCTCAAAAAAAACCAAATCTTCAAAACT.  
For each gene, CpG sites with missing values in more than the 20% of the samples were removed, 
as well as samples with missing values in more than the 20% of CpG sites. The R package 
massArray was used to test if bisulphite conversion reaction run to completion [24]. For all samples 
analysed bisulphite conversion was from 98.9% to 100%. 
 
 
Mixed Leukocyte Reaction Assay 
The T cells were used as autologous responder cells for in vitro suppression assays. The suppressive 
activity of freshly isolated and expanded cells were tested by co-culturing CD8-CD25- T cells, 
labeled with 5 µM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), with serial dilutions 
of freshly isolated (CD8-CD25+ T cells) and ex vivo expanded autologous Tregs in the presence of 
CD3/CD28 GMP beads at ratio previously shown by us (in house experiments) to be effective in 
dose-response experiments (1:10 CD8-CD25-T cells to bead ratio) in RPMI-1640 medium 
containing 10% FBS, 1% penicilline/streptomycine and L-glutamine (1%)  for 5 days at 37°C and 
5% CO2. Proliferation was analyzed by flow cytometry. The percentage of proliferative CD8-
CD25- T cells in the absence of Tregs was taken as 100% proliferation.  
 
 



































































The GMP manufacturing was performed in the Cell Factory  of Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico, certified in compliance with European GMP regulations by the 
Italian Drug Agency (authorization number aM-51/2018). 
Steady state leukapheresis from 2 patients (1 KT and 1 LT patient) were processed using GMP-
compliant devices and reagents (Supplementary Figure 1A). The subjects were evaluated for 
venous accesses suitability. Leukapheresis was carried out by the COM.TEC® (Fresenius Kabi AG, 
Bad Homburg, Germany) cell separator. The treatment of two blood volumes was set up as the 
procedure end-point. ACD-A was used for anticoagulation at a ratio of 1:14- 1:13. For prophylaxis 
of citrate-related hypocalcemia, calcium gluconate was administered intravenously during the 
leukapheresis.  
CD8-CD25+ cells were purified using the CliniMACS System (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to GMP procedures and following manufacturer’s instructions. 
Briefly, we performed a sequential two-step process based on the magnetic depletion of CD8+ T 
cells, followed by a positive selection of CD25+ cells after an over night storage, using monoclonal 
antibodies anti-CD8 (Miltenyi Biotec) and anti-CD25 (Miltenyi Biotec), as described in the 
CliniMACS user manual for cell preparation, magnetic labelling, and selection.  
Forty millions of CD8-CD25+ cells were expanded in vitro in gas-permeable culture bags (MACS 
GMP Cell Expansion Bags and MACS GMP Cell Differentiation Bags, Miltenyi Biotec) for 3 
weeks in complete medium, consisting of TexMACS Medium (Miltenyi Biotec) supplemented with 
100 nM rapamycin (Miltenyi Biotec), 5% allogeneic human heat-inactivated AB plasma, 500-1000 
UI/mL IL-2 (Proleukin, Novartis Pharmaceuticals Canada Inc, Dorval, Quebec, Canada). On day 0, 
7 and 14, anti-CD3/CD28 beads (MACS GMP ExpAct Treg Beads, Miltenyi Biotec) were added at 
different beads:cells ratio 4:1, 1:1, 1:1 respectively. 
At day 21 all the cultured cells were collected and the beads were removed using the CliniMACS 
device, according to manufacturer’s instructions. Cells were counted by an automated and validated 



































































evaluated by flow cytometry (BD FACSCanto II, BD Bioscience, San Jose, CA, USA)  using the 
following antibodies: CD45 APC-H7 (BD Bioscience), CD4 FITC (BD Bioscience), CD25 APC 
(BD Bioscience), CD127 PE-Cy7 (BD Bioscience) and FoxP3 PE (eBioscience, San Diego, CA, 
USA). 
Negative fraction (CD8-CD25- T cells) after GMP selection at day 0 and the final product after 
GMP expansion at day 21, were cryopreserved and thawed as above described.  
 
 
Cryopreservation and thawing of freshly isolated and expanded cells  
Freshly isolated fractions  (CD8-CD25+ and CD8-CD25- T cells) and expanded cells (after 7, 14 
and 21 days of expansion) were washed and cryopreserved with 10% DMSO (CRYOSERV, Mylan 
Institutionals, Canonsburg, PA, USA), 10% HSA (HAS; Kedrion, Lucca, Italy) in a saline solution 
(B. Braun, Melsungen, AG, Germany) using a controlled-rate freezer. The frozen units were 
transferred and stored immediately to vapor-phase liquid nitrogen into dedicated tanks. All the 
cellular fractions were thawed at 37°C and the viability, phenotype and suppressive function were 
assessed as above described. 
 
 
Xenogeneic GVHD mouse model 
NOD scid gamma (NSG) female mice (6-7 weeks  of age)  were purchased from Charles River 
(Calco, Italy). All animals were housed under specific pathogen-free conditions in compliance with 
guidelines of the San Raffaele Institutional Animal Care and Use Committee (IACUC number: 
632). Mice were maintained for at least 5 days in the animal facility for acclimatization before 
transplantation. To promote the engraftment of transplanted cells injected intraperitoneally, all mice 
were conditioned with total body irradiation (1.75 cGy) on day 1. Of note,  day 1 of the study is 



































































monitored for 7 weeks. Clinical signs of GVHD (e.g., hunched back, fur loss, skin inflammation) 
were monitored daily. Body weight was monitored throughout the duration of the study. Animals 
showing marked clinical signs as of distress, loss of weight equal to or greater than 20% of their 
starting weight were immediately sacrificed. 
To establish whether the expanded Tregs could counteract acute GVHD, a xeno-GvHD model was 
induced by intraperitoneally transfer of  human autologous CD8-CD25- T cells from 1 LT and 1 KT 
patient into mice. Both CD8-CD25- T cells and expanded Tregs were injected within 30 minutes 
from thawing (Supplementary Figure 1 B). Specifically, human CD8-CD25- T cells (6x106) from 
LT or KT patients were injected with (simultaneous injection) or without autologous Treg (6x106) 
at a Treg: CD8-CD25- T cells ratio of 1:1. Timing of Treg infusion is crucial. In our model Tregs 
were infused at the time of  T effector transplantation.  
 
 
In vivo engraftment monitoring 
To assess the in vivo persistence of human cells, transplanted mice were bled 4 weeks after 
transplantation and sacrificed 7 weeks after transplantation. Phenotype analysis of injected cells and 
of peripheral blood  at 4 weeks (± 3 days) after transplantation and of PB and spleen at 7 weeks (± 3 
days) after transplantation was performed (Supplementary Figure 1C). Following a Fc blocking 
step, cell surface staining was performed with anti-mouse CD45 and anti–human CD4, CD3, CD25, 
FoxP3 mAbs at 1:100 dilution in staining buffer (PBS, 2% FCS, 0.1% NaN3) (list of mAbs is in 
Supporting Information Table). To detect FoxP3, cells were treated and stained with the FoxP3 
fixation/permeabilization kit according to the manufacturer’s instructions (eBioscience). Samples 
were acquired on a BD FACSCanto II flow cytometer. Manual analysis of flow cytometry data was 
performed with FCS Express V4 (DeNovo Software, Glendale, CA). 
 




































































Statistical analyses were performed using GraphPad Prism (GraphPad Prism 5.0 soft-ware, 
SanDiego CA, USA), and data are presented as mean ± standard error of the mean (SEM).  For all 
experiments involving multiple comparisons, analysis of variance (ANOVA) followed by a  
Dunnett’s post hoc test was used. For those who involved comparisons between two groups, 







Enumeration of circulating Treg from LT and KT patients 
We firstly enumerated circulating CD4+CD25+CD127-FoxP3+ Tregs in End-Stage Organ Disease  
patients and controls. The mean absolute numbers of circulating Tregs from LT  (19.8±10/mL) and 
KT (18.8±7/mL) patients was not significantly different from that of healthy controls (17±4/mL) 
(p=NS; Supplementary Figure 2).  
 
 
Tregs isolation, expansion, cryopreservation and thawing 
Starting from 60 ml of PB (patients) and 30 ml of buffy-coat (healthy controls), CD8 depletion with 
subsequent CD25+ enrichment of PBMCs yielded a median of 3.7x106 nucleated cells (range 1.28-
8.8x106) in healthy controls, 1.47x106 nucleated cells (range 5.3x105-2.56x106) in LT patients and 
1.77x106 nucleated cells (range 8.5x105-2.7x106) in KT patients. The freshly isolated CD8-CD25+ 
T cells were 2.0± 1.2 , 1.9±1.3   and 2.6%±0.7  of the PBMCs, respectively, with no significant 



































































strategy for identification of CD4+CD25+CD127-FoxP3+ Tregs which represented more than 80% 
of the cells (range 70-96%) within the CD8-CD25+ population.  The median Treg purity 
(CD4+CD25+CD127-FoxP3+ cells) was 72% (range 50-84) and  55% (range 40-70) in LT and KT 
patients, respectively and 65% (range 54-80) in healthy controls (Figure 1B). No significant 
difference was observed between patients and controls (p=NS). On day 0, contaminating cells in 
healthy controls were CD19+ B cells (16%, range 14.8-17), Th17 cells (4.7%, range 0.7-6.9) and 
CD14+ monocytes (6.3%, range 0.8-11.4). In LT and KT patients, contaminating cells were mainly 
CD19+ B cells (6.8%, range 1.1-8.4; 5.4%, range 1.9-8.9, respectively) and Th17 cells(7.3%, range 
1.4-12.8; 11.8%, range 10.3-13.3, respectively). Natural Killer cells  and monocytes content was 
always very low (below 1%) (Figure 1C). By comparing patients and controls, Th17 cells were 
significantly increased in KT cells as compared with LT or healthy controls (p≤0.05vs LT patients; 
p≤0.05 vs healthy controls). In addition, CD19+ cells were significantly reduced in both patient 
groups as compared with the normal counterparts (p≤0.05 for LT patients; p≤0.05 for KT patients). 
After 21 days, Tregs expanded a median of 197-folds (range 26-567) in LT patients, 266-
folds (range 233-300) in KT patients and 559-folds (range 342-826) in healthy controls (Figure 
2A). Differences between patients and controls were not statistically significant. Starting from 
freshly isolated 500x103 cells, the final yield was a median of 255x106 (range 171x106-413x106) 
nucleated cells in healthy controls, 48x106 (range 30x106-284 x106) nucleated cells  in LT patients 
and 133 (range 116x106-150x106) nucleated cells in KT patients (data not shown). Treg purity 
(CD4+CD25+CD127-FoxP3+) increased significantly during expansion (Figure 2B) in healthy 
donors and KT patients  (p≤0.05). Contaminating cells, namely  B cells, Th17 cells and monocytes 
decreased below 1% in healthy controls and  LT patients and below 3% in KT patients (Figure 2C).   
When cryopreserved/thawed 21 days expanded Tregs were analyzed, the mean percentage of 
viable cells was always more than 75% with no significant differences between patients and 
controls (Figure 2D). The mean percentage of CD4+CD25+CD127-FoxP3+ cells was always 



































































When functional assays were performed, freshly isolated cells (CD8-CD25+ T cells) from 
the three groups exerted a limited (healthy controls and  LT patients) or poor (KT patients) 
suppressive effect toward autologous CD8-CD25- T cells proliferation in vitro (Figure 3A). After 
21 days of in vitro expansion, flow cytometry analysis demonstrated that, according to the increased 
T regulatory phenotype, Tregs from patients/controls had significant suppressive activity (Figure 
3B), which was not  modified by cryopreservation/thawing (Figure 3C). 
All together these data demonstrate that our small scale Treg isolation and expansion 
protocol from LT and KT patients lead to functional Tregs which are suitable for cell therapy. 
Moreover, cryopreservation/thawing does not impair phenotype/function of the expanded Tregs. 
 
 
FOXP3 methylation analysis 
Figure 4A shows that in males the locus, which is localized on X chromosome, displayed low DNA 
methylation values (CpG sites ranging from 0.08 to 0.44). As expected, in females CpG sites had 
higher methylation values (ranging from 0.24 to 0.73) due to X chromosome inactivation We 
evaluated DNA methylation differences at day +21 in freshly isolated and cryopreserved/thawed 
expanded cells in patients and controls separately using paired t-test. The large majority of CpG 
sites was not significant, and intra-individual difference between the two groups were generally 
small, spanning between -0.13 and 0.23. The only exception was the CpG_3 among controls (p-
value: 0.002), but, also in this case, the difference between the freshly isolated and the 
cryopreserved/thawed cells was small, ranging from 0.06 to 0.07 (Figure 4B).   
Collectively, these data suggest that the DNA methylation pattern of FOXP3 gene is 






































































In vivo study 
To investigate whether GMP expanded Tregs from 1 KT and 1 LT patient have inhibitory 
function in vivo after thawing, we used a xenograft model of lethal GVHD. Specifically, irradiated 
NSG mice were injected with cryopreserved/thawed CD8-CD25- T cells either alone or in 
combination with autologous expanded  cryopreserved/thawed Tregs at 1:1 ratio to assess their 
ability to ameliorate GVHD (Supplementary Figure 1). The rationale for this design is that early 
infusion of Tregs allows the cells to prevent T effector activation.  After the immunomagnetic 
selection and expansion of 40 millions of freshly isolated CD8-CD25+ cells under GMP condition, 
we obtained 4.3x109 total cells (107.1- fold expansion) for the KT patient and 4.6x109  total cells 
(115.2- fold expansion) for the LT patient. Before expansion the percentage of 
CD45+/CD4+/CD25+ cells was 84.9 % and 53.9% in KT and LT patient whereas , at the end of 
expansion, the percentage of CD45+/CD4+/CD25+ cells  increased up to 98.3% and 89.2% 
respectively. At day 21 CD45+/CD4+/CD25+/CD127-/FoxP3+ cells were 79.2% and 84.4% 
respectively (data not shown). 
Tregs were then thawed and characterized for the phenotype and in vitro function. As shown 
in Figure 5A and B, the thawed Tregs were more than 80% CD4+CD25+CD127-FoxP3+ and 
highly suppressive.  
Mice receiving KT CD8-CD25- T cells lost weight and all succumbed to GVHD by day 40. 
In contrast, mice receiving KT CD8-CD25- T cells and autologous Tregs showed delayed disease-
associated weight loss and slightly increased survival rate (by day 48 17% of mice receiving CD8-
CD25- T cells with Tregs from the KT patient survived vs 0% for mice receiving CD8-CD25- T 
cells only; p=N.S.) (Figures 6A and B). Similar results were obtained with cells from the LT 
patient: by day 48 58% of mice receiving CD8-CD25- T cells with Tregs from the LT patient 
survived vs 12,5% for mice receiving CD8-CD25- T cells only (p=N.S.; Figure 6C and D) 
To assess human cells engraftment in PB, animals were bled after 4/7 weeks and the 



































































shown in Figure 7A. No human CD45+ cells were identified in the PB of mice after infusion of 
Tregs alone from KT or LT patients. Conversely, a wide distribution of human CD45+ cells was 
observed in the PB of mice after transplant of CD8-CD25- T cells alone or CD8-CD25- T cells plus 
Treg infusion (Figure 7 B and C).  
To assess the biodistribution of infused human cells, spleen and PB cells of mice were 
stained with anti-human CD45, CD3, CD4, FoxP3 monoclonal antibodies after 7 weeks from 
transplant. The gating strategy is shown in Figure 8A. By comparing PB and spleen, a higher mean 
percentage of human CD45+ cells was observed in the spleen vs PB of the mice after receiving 
CD8-CD25- T cells plus Treg of LT patients (p<0.003; Figure 8B). Of note, the majority of the 
human CD45+ cells were CD3+CD4+ in the blood/spleen of mice after receiving KT or LT cells 
(Figure 8C). Human FoxP3+ Tregs were identified in the CD3+CD4+ fraction of PB and spleen of 





The use of Tregs for the treatment of GVHD and for inducing operational tolerance after solid 
organ transplantation is a promising approach.  
Here, we isolated, expanded and functionally characterized Tregs from patients with end 
stage kidney and liver disease, with the aim to establish a suitable method to obtain 
immunomodulatory cells for adoptive immunotherapy post-transplantation. 
We demonstrated that fully functional Tregs from patients in waiting list for solid organ 
transplantation can be isolated/expanded for clinical studies. These cellular products show 
homogenous regulatory T cells characteristics with very low percentage of contaminating cells. 



































































isolated/expanded Tregs from KT and LT patients are similar. Interestingly, our 
cryopreservation/thawing procedure allowed cell suspensions with phenotype/function and 
hypomethylation of the FOXP3 gene superimposable to that of the freshly isolated counterparts. 
This finding challenges the notion that cryopreservation of Tregs products is detrimental for their 
function [26-27].  
Our freshly isolated cells from healthy donors and LT/KT patients  showed limited 
suppressive activity.  This is in contrast with previous findings demonstrating 60-80% of 
suppressive activity by freshly isolated healthy donors cells, which were CD8-CD19-CD25+ cells 
[22] or CD8-CD25+ cells [25]. However, our results  may be due 1) to the low purity of our freshly 
isolated cell suspension (CD8-CD25+ cells) and 2)  to the fact that while our suppressive activity 
results were based on a  1:2 Treg/CD8-CD25- T cells working ratio, their  ratio was 1:1 Treg/Teff. 
Whether this results is also due to the fact that our freshly isolated healthy donors cells derive from 
24 hours aged buffy-coats remains a matter of speculation.  
Safinia et al firstly proposed a GMP production protocol to expand CD25+-enriched cells 
from PB in the presence of IL-2 and rapamycin to induce tolerance after liver transplantation [10]. 
In their 36 days expansion protocol, multiple round of in vitro Treg stimulation were necessary to 
achieve clinically relevant Tregs number. In our protocol indeed, we obtained fully functional Tregs 
after 21 days of expansion containing less than 1% of contaminating CD8+ effector cells. 
Expanded, cryopreserved and thawed Tregs remain hypomethylated at intron 1 of the FOXP3 locus, 
confirming their epigenetic stability. Functionally, Tregs showed suppressive function against 
autologous CD8-CD25- T cells. 
Several human Treg products have been tested in animal models. However, previous data of 
Treg cell infusion in non human primates report conflicts regarding the ability of the infused cells to 
induce transplant tolerance [28-30]. Thus, we decided to use a mouse model of GVHD in 



































































with or without GMP Tregs to prevent the onset of xenogeneic GVHD. In our mouse model, GMP 
Tregs from LT or KT patients proved to be safe and showed  a trend toward reduced lethality of 
acute GVHD in vivo. Interestingly, GMP Tregs from LT and KT patients did not induce xenogenic 
GVHD and did not expand as documented by the absence of Tregs in the PB and spleen of mice 
after 4 and 7 weeks from transplantation. This is probably due to the lack of human IL-2.  
Nevertheless, our data are consistent with previous models of xenogeneic GVHD and Treg 
infusion. The addition of CD25 expressing cells to human PBMC showed the amelioration of 
xenogeneic GVHD, whereas the depletion of all CD25+ cells led to the development of lethal 
xenogeneic GVHD [31]. Also, in-vitro expanded Tregs from human peripheral blood or cord blood 
were able to ameliorate or suppress xenogeneic GVHD [32,33]. More recently, it has been reported 
that the infusion of polyclonal human Tregs improved murine xenogeneic chronic GVHD [34]. In 
addition, Del Papa et al. used a similar methodology ( immune-magnetic Treg isolation and 
polyclonal expansion in the presence of CD3/CD28 beads, IL-2, and rapamycin for 19 days) 
achieving a median of  8.5 fold expansion and maintaining FoxP3 expression over the culture 
period. NSG mice that received human leukemic cells and expanded Tregs with conventional T 
cells were rescued from leukemia and survived without GVHD. Mice that received leukemic cells 
plus conventional T cells died of severe GVHD within 70 days [22].  
 
CONCLUSION 
In summary, we demonstrated that expanded/thawed GMP Tregs from two different groups 
of patients with end-stage organ failure were fully functional in vitro and their infusion was safe and 
resulted in a trend toward reduced lethality of acute GVHD in vivo. These data further support the 
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Legend to figures 
 
Fig 1.  Phenotype of the freshly isolated Tregs. A. The gating strategy  of Tregs identification 
after CD8 depletion and CD25 enrichment is shown.  Dot plots depict the expression of CD25, 
CD127 and FoxP3. Interestingly,  the majority of the freshly isolated cells expressed CD25. Dot 
plots are representative of  11 independent experiments from patients/controls. B. Graph shows 
Treg purity, as  percentage of CD4+CD25+CD127-FoxP3+ cells after isolation from PB of CTR, 
LT and KT patients. No significant difference was observed between patients and controls (p=NS). 
C. Graph displays the percentages of contaminant cells in the freshly isolated product from CTR, 
LT and KT patients. Data are represented as mean± SEM. (*p<0.05) 
 
Fig 2. Phenotype of the in vitro expanded Tregs. A. Tregs from CTR, LT and KT patients were 
expanded up to 21 days with IL-2 and Rapamycin. Fold expansion of day 7,  14 and  21 was 
calculated as compared to day 0 seeded cells. B. Graph shows the percentage of Treg 
(CD4+CD25+CD127-FoxP3+) at each time point stimulation. Treg purity increased significantly 
during expansion in CTR and KT patients.  C. The graph shows the percentages of contaminant 
cells during the expansion period. The contaminant cells  decreased  below 1% in CTR and  in LT 
patients and below 3% in KT patients at the end of expansion. D. Viability of cryopreserved/thawed 
day 21 Tregs is shown. No significant difference was observed between patients and CTR (p=NS). 
E. Phenotype of the cryopreserved/thawed day 21  Tregs is shown as mean percentages of 
CD4+CD25+CD127-FoxP3+ cells. The thawed Tregs were almost all FoxP3 positive in 
patients/CTR. No significant difference was observed between patients and controls (p=NS). Data 
are represented as mean± SEM. (*p<0.05) 
 
 Fig 3. Suppressive function of the in vitro expanded Tregs.  The graphs show the mean 
percentages of proliferation of  the CFSE-labelled  autologus CD8-CD25- T cells  in the presence of 
CD3/CD28 GMP beads  and Tregs at different ratios. A.  MLR with freshly isolated Tregs  (day 0). 
Freshly isolated  Tregs from the three groups were limited (CTR and  LT patients) or very poorly 
(KT patients) suppressive. B. MLR with freshly isolated expanded Tregs (day 21). Expanded Tregs 
from patients/CTR had significant suppressive activity at 1:2  and 1:4 (Treg:CD8-CD25- T cells) 
ratio. C. MLR  with expanded  and cryopreserved/thawed day 21 Tregs. Cryopreservation/thawing 
did not significantly affects the suppressive activity of day 21 expanded Tregs of patients/CTR. 
Data are represented as mean± SEM. (*p<0.05,**p<0.01,***p<0.001) 
 
 
Fig 4.  DNA methylation analysis of FOXP3 intron 1. A. DNA methylation values of FOXP3 
intron 1 in day +21 freshly isolated GMP expanded Tregs from patients/healthy controls. B. 
Differences in DNA methylation values of FOXP3 locus between day +21 freshly isolated and day 
+21 cryopreserved/thawed GMP expanded Tregs. In both the panels blue and pink lines correspond 
to male and female subjects respectively, while continuous and dashed lines correspond to healthy 
controls and patients respectively. 
 
 
Fig 5. GMP Treg expansion for the in vivo study: phenotype and function of  
cryopreserved/thawed day 21 expanded Tregs. A. Graph shows the percentages of 
CD4+CD25+CD127-FoxP3+ Tregs of the LT and KT patient after thawing. Almost all cells were 
FoxP3 positive. B.  MLR assay is shown. Expanded Tregs from the LT or KT patient had 





































































Fig 6. In vivo study: injection of cryopreserved/thawed GMP day 21 Tregs from 1 KT and 1 
LT patient in a xenogeneic GVHD murine model.  A and C show the percentage of body weight 
variation of mice receiving CD8-CD25- T cells only,  GMP Tregs only or  GMP Tregs plus CD8-
CD25- T cells from KT and LT patients, respectively. Data are presented as means  (KT/LT: CD8-
CD25- T cells n=7/8 mice; GMP Tregs n=6/6 mice; GMP Tregs plus KT CD8-CD25- T cells 
n=12/12 mice). B and D show the survival rate of mice receiving CD8-CD25- T cells only, GMP 
Tregs only or GMP Tregs plus KT CD8-CD25- T cells from KT and LT patients, respectively. 
(survival of mice receiving KT cells: statistically significant differences were observed only for 
Tregs vs CD8-CD25+  cells (P<0.001) and Tregs vs CD8-CD25+ cells + Tregs (P<0.01); survival 
of mice receiving LT cells: statistically significant differences were observed only for Tregs vs 
CD8-CD25+ cells (P<0.05)). Overall, mice receiving GMP Tregs plus CD8-CD25- T cells showed 
a trend toward  a time delay in body weight loss and survival as compared with mice injected with 
CD8-CD25- T cells only.  
  
 
Fig 7. In vivo study: human CD45+ cells engraftment in the xenogeneic GVHD murine model. 
Animals were bled after 4/7 weeks and the percentages of human CD45+ cells in blood was 
determined by flow cytometry. A. Representative dot plots of human CD45+ cell engrafment  at 4 
weeks after transplant are shown. B and C. No human CD45+ cells were identified in the PB of 
mice after infusion of Tregs alone  from the KT or LT patient. Conversely,  a wide distribution of 
human CD45+ cells were observed in the PB  of mice after transplant of KT/LT CD8-CD25- T cells 
alone or CD8-CD25- T cells plus Treg infusion. In addition to individual data, mean values and 
SEM are shown. 
 
Fig 8. In vivo study: biodistribution of the infused GMP Tregs. Suspensions of spleen and PB 
after 7 weeks from transplant were stained with anti-human CD45, CD3, CD4, FoxP3 monoclonal 
antibodies and flow cytometry analysis was performed.  Panel A depicts the gating strategy  to 
identify the selected subpopulations. Panels B, C and D show the percentages of human CD45+, 
CD3+CD4+ and FoxP3+ Treg cells  in the blood and spleen of  mice after transplant of KT/LT 
CD8-CD25- T cells plus Treg. In addition to individual data, mean values and SEM are shown.  
 
 
Supplementary Fig 1.  Design of the in vivo study. A. Steady state leukapheresis from 2 patients 
(1 KT and 1 LT patient) were processed using GMP-compliant devices and reagents. Tregs positive 
fraction (CD8-CD25+ cells) was purified using the CliniMACS System. Forty millions of CD8-
CD25+ cells were expanded in vitro  for 3 weeks. At day 21 all the cultured cells were collected 
and the beads were removed using the CliniMACS device, according to manufacturer’s instructions.  
Negative fraction (CD8-CD25- T cells) after GMP selection at day 0 and the final product after 
GMP expansion at day 21 were cryopreserved and thawed as described in Material and Methods 
section.  B. Irradiated NSG mice were infused with the KT or the LT CD8-CD25- T cells, either 
alone or in combination with autologous expanded  Tregs at 1:1 ratio, to assess their ability to 
ameliorate GVHD. C. Mice were bled 4/7 weeks after transplantation and sacrificed 7 weeks after 
transplantation. FACS analysis of the injected cells (day 1), of PB (4 weeks ± 3 days after 
transplantation) and of PB and spleen (7 weeks ± 3 days after transplantation) was performed. 
 
Supplementary Fig 2.  Circulating Tregs in KT and LT patients.  Mean absolute number of 
circulating CD4+CD25+CD127-FoxP3+ Tregs from healthy controls and  selected LT and KT 





































































 Table I. Patients characteristics 
 KT LT CTR 
Total number 9 14 10 
Sex (male/females) 3/6 8/6 5/5 
Age (years; mean±SD) 53±13 61±10 58±12 
Disease    
HCV/HBV liver 
cirrhosis  
N=0 N=8 NA 
Alcoholic liver 
cirrhosis 
N=0 N=3 NA 
Dysmetabolic liver 
cirrhosis 
N=0 N=2 NA 
Cryptogenetic liver 
cirrhosis 
N=0 N=1 NA 
Epatorenal polycystic 
disease 
N=4 N=0 NA 
End stage kidney 
disease  




N=1 N=0 NA 








































































Supplementary Table 1. 
 





CD4-FITC (SK3), CD25-PeCy7 (2A3), CD127-
PE/APC (hIL-/R-M21), CD45-PerCpCy5.5 
(2D1), from BD-Biosciences; CD25-Biotin 
(4E325) and Biotin-APC from Miltenyi; FoxP3-
PE (PCH101) from eBioscience. 
Contaminant cells (T cells, B cells, NK cells, 
Th17 cells, monocytes) 
 
CD19-FITC (4G7), CD14-PeCy7 (MoP9), 
CD56-APC (NCAM16.2), CD8-PE (SK1) and 
CD196-PE (11A9) from BD-Biosciences; 
CD161-FITC (191B8) from Miltenyi. 
In vivo experiments: 
 
Human and mouse CD45+ cells 
Human CD3+CD4+ 
Human FoxP3+ Treg 
Anti–human CD45-Brilliant Violet510 (HI30), 
CD4 Pacific Blue (RPA-T4), FoxP3 Alexa 
Fluor 488 (259D) from Biolegend. Anti-human 
CD3-APC-Vio770(BW264/56) and anti-mouse 
CD45 Percp from  Miltenyi Biotech. CD25 
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